A Phase 1/2 Multicenter, Open-label, Dose-escalation, Safety, Pharmacodynamic, and Pharmacokinetic Study of Q901 Administered via Intravenous Infusion in Adult Patients with Selected Advanced Solid Tumors with a Cohort Expansion at the Recommended Phase 2 Dose
NCT #
NCT05394103
Condition(s)
Breast Cancer, Colorectal Cancer, Lung Cancer (SCLC), Ovarian/ Peritoneal/ Fallopian Tube Cancer, Pancreatic Cancer, Prostate Cancer
Molecular Target(s)
CDK7
Drug Classification(s)
Small Molecule
Agents(s)
Q901
Phase(s)
I/II
Mechanism of Action
Q901 is a small molecule inhibitor for CDK7 kinase activity, thereby inhibiting CDK7-mediated signaling. Inhibition of CDK7 may inhibit tumor cell proliferation via inhibiting cell cycle progression, such as CDK1, 2, 4 and 6.
Purpose
- How much of the study can be given with an acceptable level of side effects
- The effects of the study (good and bad)
- The dose of the study drug that should be used in future studies
- How much of the study is absorbed into the blood and how fast it is removed
- How the study is acting on your body
Location
MCD
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.